Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?

In kidney cancer, a regimen of Bristol Myers Squibb’s Opdivo and Yervoy, and an Opdivo combination with Exelixis’ Cabometyx, have both been approved in newly diagnosed patients. Now, Exelixis suggests the three drugs could be paired together.